宿主靶向抗乙型肝炎病毒治疗策略研究新进展*

doi:10.3969/j.issn.1672-5069.2023.03.038

Abstract

Abstract: Chronic hepatitis B virus infection is an important factor in the progression of liver disease and hepatocellular carcinoma. The complete life cycle of hepatitis B virus is dependent on the host cell, which makes host-targeting antiviral (HTA) treatment options promising. The HTA includes inhibition of virus entry, destabilization of viral nucleic acids and enhancement of host immune response to HBV infection. This paper reviewed the development of medicines that target hosts and host factors in order to achieve the goal of hepatitis B virus suppression, with a view to providing a reference for subsequent antiviral research and clinical treatment.

Key words: Hepatitis B, Host-targeted antiviral treatment, Therapy

Fang Huijing, Zhu Chuanlong, Zhang Lili. Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2023, 26(3): 449-452.

References

[1] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.Gut,2015,64(12):1972-1984.
[2] Xia Y, Guo H. Hepatitis B virus cccDNA: formation, regulation and therapeutic potential.Antiviral Res,2020,180:104824.
[3] Lee HW, Lee JS, Ahn SH. Hepatitis B virus cure: targets and future therapies.Int J Mol Sci,2020,22(1):213.
[4] Wang J, Huang H, Liu Y, et al. HBV genome and life cycle.Adv Exp Med Biol,2020,1179:17-37.
[5] Bruss V, Hagelstein J, Gerhardt E, et al. Myristylation of the largesurface protein is required for hepatitis B virusin vitro infectivity.Virology,1996,218(2):396-399.
[6] König A, Döring B, Mohr C, et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na⁺/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.J Hepatol,61(4):867-875.
[7] Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.J Hepatol,2016,65(3):490-498.
[8] Blank A, Eidam A, Haag M, et al. The NTCP-inhibitor myrcludex b: effects on bile acid disposition and tenofovir pharmacokinetics.Clin Pharmacol Ther,2018,103(2):341-348.
[9] Shimura S, Watashi K, Fukano K, et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.J Hepatol,2017,66(4):685-692.
[10] Fukano K, Oshima M, Tsukuda S, et al. NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization.J Virol,2021,95(24):e00938-21.
[11] Hu Q, Zhang F, Duan L, et al. E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution.Front Cell Infect Microbio,2020,10:74.
[12] Appelman M D, Chakraborty A, Protzer U, et al. N-glycosylation of theNa⁺-taurocholate cotransporting polypeptide (NTCP) determines its trafficking and stability and is required for hepatitis B virus infection.PLoS One,2017,12(1):e0170419.
[13] Mueller H, Lopez A, Tropberger P, et al. PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization.Hepatology,2019,69(4):1398-1411.
[14] Sun L, Zhang F, Guo F, et al. The dihydroquinolizinone compound RG7834 inhibits the polyadenylase function of PAPD5 and PAPD7 and accelerates the degradation of matured hepatitis B virus surface protein mRNA.Antimicrob Agents Chemother,2020,65(1):e00640-20.
[15] Block TM, Young JAT, Javanbakht H, et al. Host RNA quality control as a hepatitis B antiviral target.Antiviral Res,2021,186:104972.
[16] Han X, Zhou C, Jiang M, et al. Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action.J Med Chem,2018,61(23):10619-10634.
[17] Hwang N, Sun L, Noe D, et al. Hepatoselective dihydroquinolizinone bis-acids for HBsAg mRNA degradation.ACS Med Chem Lett,2021,12(7):1130-1136.
[18] Liu F, Lee ACH, Guo F, et al. Host poly(A) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNA.J Virol,2021,95(18):e00574-21.
[19] Königer C, Wingert I, Marsmann M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses.Proc Natl Acad Sci U S A,2014,111(40):E4244-E4253.
[20] Tang L, Sheraz M, Mcgrane M, et al. DNA polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.PLoS Pathog,2019,15(4):e1007742.
[21] Qi Y, Gao Z, Xu G, et al. DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus.PLoS Pathog,2016,12(10):e1005893.
[22] Long Q, Yan R, Hu J, et al. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation.PLoS Pathog,2017,13(12):e1006784.
[23] Kitamura K, Que L, Shimadu M, et al. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.PLoS Pathog,2018,14(6):e1007124.
[24] Yang H, Zhu XQ, Wang W, et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selectivetyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.Bioorg Chem,2021,111:104881.
[25] Luo J, Luckenbaugh L, Hu H, et al. Involvement of host ATR-CHK1 pathway in hepatitis B virus covalently closed circular DNA formation.MBio,2020,11(1):e03423-419.
[26] Mohd-Ismail N K, Lim Z, Gunaratne J, et al. Mapping the interactions of HBV cccDNA with host factors.Int J Mol Sci,2019,20(17):4276.
[27] Decorsière A, Mueller H, Van Breugel P C, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.Nature,2016,531(7594):386-389.
[28] Allweiss L, Giersch K, Pirosu A, et al. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.Gut,2022,71(2):372-381.
[29] Sekiba K, Otsuka M, Ohno M, et al. Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8–activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus.Hepatology,2019,69(5):1903-1915.
[30] Suslov A, Boldanova T, Wang X, et al. Hepatitis B virus does not interfere with innate immune responses in the human liver.Gastroenterology,2018,154(6):1778-1790.
[31] Chan Y K, Gack M U. Viral evasion of intracellular DNA and RNA sensing.Nat Rev Microbiol,2016,14(6):360-373.
[32] Lanford R E, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.Gastroenterology,2013,144(7):1508-1517.
[33] Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.J Hepatol,2015,62(6):1237-1245.
[34] Tsai TY, Huang MT, Sung PS, et al. SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection.J Clin Invest,2021,131(11):e141965.
[35] Janssen HLA, Brunetto MR, Kim YJ, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.J Hepatol,2018,68(3):431-440.
[36] Herschke F, Li C, Zhu R, et al. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.Antiviral Res,2021:105196.
[37] Daffis S, Balsitis S, Chamberlain J, et al. Toll‐like receptor 8 agonist GS‐9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B.Hepatology,2021,73(1):53-67.
[38] Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic potential of TLR8 agonist GS‐9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators.Hepatology,2021,74(1):55-71.
[39] Mackman RL, Mish M, Chin G, et al. Discovery of GS-9688 (selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B.J Med Chem,2020,63(18):10188-10203.
[40] Embrechts W, Herschke F, Pauwels F, et al. 2, 4-Diaminoquinazolines as dual toll-like receptor (TLR) 7/8 modulators for the treatment of hepatitis B virus.J Med Chem,2018,61(14):6236-6246.
[41] Ouaguia L, Dufeu‐Duchesne T, Leroy V, et al. Hepatitis B virus exploits C‐type lectin receptors to hijack cDC1s, cDC2s and pDCs.Clin Transl Immunol,2020,9(12):e1208.
[42] Sato S, Li K, Kameyama T, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus.Immunity,2015,42(1):123-132.
[43] Korolowicz KE, Iyer RP, Czerwinski S, et al. Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B.PLoS One,2016,11(8):e0161313.
[44] Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study.J Hepatol,2019,71(5):900-907.
[45] Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.JHEP Rep,2021,3(6):100361.
[46] Wang W, Zhou X, Bian Y, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B.Nat Nanotechnol,2020,15(5):406-416.
[47] Ma A, Motyka B, Gutfreund K, et al. A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B.Hum Vaccin Immunother,2020,16(4):756-778.
[48] Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current status of therapy and future therapies.Gastroenterol Clin North Am,2020,49(2):215-238.
[49] Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy.Curr Opin Immunol,2020,66:35-41.
[50] Zhang H, Wang F, Zhu X, et al. Antiviralactivity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection.Clin Infect Dis,2021,73(2):175-182.

Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tao Zhenzhen, Wang Yongli, Sun Hongyan, et al.. Comparison of different Young's modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 328-331.
[2]	Zhao Jing, He Xiubo, Chen Jinhuan. Early diagnosis of significant liver fibrosis by liver shear wave elastography and GGT/PLT ratio in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 332-335.
[3]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[4]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.
[5]	Wang Yunyun, Wu Wanfeng, Li Li. Antiviral efficacy and impact on blood glucose control of direct acting antivirals in treatment of patients with genotype 1b chronic hepatitis C and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(3): 344-347.
[6]	Xu Haimiao, Zheng Ruiqi, Ding Huiguo. Short-term efficacy of pitavastatin and polyene phosphatidyl choline combination in the treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 352-355.
[7]	Guo Yinyan, Yue Zhi, Gai Xiaodong, et al.. Clinical and liver pathological features of patients with autoimmune hepatitis- primary biliary cholangitis overlap syndrome [J]. Journal of Practical Hepatology, 2023, 26(3): 372-375.
[8]	Wang Junhong, Dai Ling, Chen Guobin, et al.. Cost-effectiveness analysis of reduced glutathione,diammonium glycyrrhizinate and glycyrrhizin in the treatment of patients with anti-tuberculosis medicine-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 380-383.
[9]	Wei Dongping, Han Lili, Ling Jiahui, et al.. Efficacy of glycyrrhizic acid diamine and compound glycyrrhizin in the treatment of patients with cyclophosphamide-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 388-391.
[10]	Liu Kun, Xu Jing, Ma Zhufang. Transient improvement of patients with liver cirrhosis-induced refractory ascites by oral tolvaptan administration at base of concentrated ascites reinfusion [J]. Journal of Practical Hepatology, 2023, 26(3): 396-399.
[11]	Tang Liang, Chen Xi, Wang Wengao. Short-term clinical efficacy of TACE and 3D-CRT in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(3): 416-419.
[12]	Zhang Wei, Chen Guolin, Wang Hang, et al.. Clinical feature of patients with pyogenic liver abscess with different underlying diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 424-427.
[13]	Zhang Qiong, Chen Shiying, Xia Wei. Comparison of anhydrous ethanol and lauromacrogol sclerotherapy under ultrasound guidance in the treatment of patients with simple hepatic cysts [J]. Journal of Practical Hepatology, 2023, 26(3): 428-431.
[14]	Wu Zhengdong, Xu Gang, Mu Haifeng, et al.. Early LC after ERCP and EST is beneficial in the treatment of patients with simultaneous gallbladder and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(3): 432-435.
[15]	Zhu Ligang, Wang Tao, Zhou Weiwei, et al.. Comparison of laparoscopic hepatectomy and percutaneous transhepatic choledochoscopic lithotomy in the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(3): 436-439.